Harbour BioMed has entered into a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb aimed at advancing the discovery and development of next-generation multi-specific antibody therapies. The partnership brings together Harbour BioMed’s antibody discovery technologies with Bristol Myers Squibb’s global drug development and commercialization capabilities, highlighting continued industry interest in complex biologics that can address challenging immune and oncology indications.
Under the terms of the agreement, the two companies will collaborate on multiple antibody discovery programs focused on multi-specific formats. These therapies are designed to target more than one disease-related pathway simultaneously, an approach that has gained momentum as researchers seek more precise and potent treatments for cancer and immune-mediated diseases. Harbour BioMed will contribute its proprietary Harbour Mice® fully human antibody technology platform, which is designed to efficiently generate high-quality, fully human antibodies suitable for therapeutic development.
Financially, the agreement provides Harbour BioMed with the potential for significant near- and long-term returns. The company is eligible to receive up to $90 million in upfront and research-related payments tied to the collaboration. In addition, Harbour BioMed could earn development and commercial milestone payments totaling up to $1.035 billion if Bristol Myers Squibb elects to advance all potential programs arising from the partnership. Tiered royalties on future product sales are also included, providing ongoing revenue should any of the partnered candidates reach the market.
The scale of the deal underscores Bristol Myers Squibb’s continued focus on expanding its biologics pipeline through external innovation. Multi-specific antibodies, which can engage multiple targets or immune cells at once, are viewed as a promising frontier in oncology and immunology. These therapies have the potential to deliver enhanced efficacy compared with traditional monoclonal antibodies, particularly in complex diseases where single-target approaches have shown limitations.
Harbour BioMed’s leadership emphasized that the collaboration goes beyond discovery alone. According to Founder, Chairman and CEO Jingsong Wang, the partnership also creates opportunities to leverage the company’s established development infrastructure in China. By potentially conducting early-stage clinical trials locally, Harbour BioMed aims to accelerate the transition of promising antibody candidates from preclinical research into human testing, shortening development timelines and generating early clinical data more efficiently.
The collaboration reflects a broader trend in the global biopharmaceutical sector, where large pharmaceutical companies increasingly partner with biotechnology firms that offer differentiated platforms and regional development strengths. For Harbour BioMed, the agreement validates its antibody discovery capabilities and positions the company as a strategic partner for multinational drug developers seeking access to innovative biologic technologies.
From Bristol Myers Squibb’s perspective, the deal complements its existing research efforts in immuno-oncology and immune-mediated diseases. By tapping into Harbour BioMed’s Harbour Mice® platform, Bristol Myers Squibb gains access to a diverse pool of fully human antibodies that can be engineered into multi-specific formats, potentially expanding the range of therapeutic options across multiple disease areas.
While specific target programs under the collaboration have not been disclosed, both companies indicated that the focus will be on advancing next-generation biologics with the potential to deliver meaningful clinical benefits for patients. The long-term nature of the agreement suggests that multiple candidates could emerge over time, offering sustained innovation rather than a single asset-driven partnership.
Overall, the collaboration positions Harbour BioMed and Bristol Myers Squibb to jointly explore the growing potential of multi-specific antibodies. If successful, the partnership could lead to the development of transformative therapies that address unmet medical needs in immunology and oncology, while also delivering substantial value to both companies through shared expertise, global reach and complementary capabilities.